

ANNUAL HEALTH INSURANCE TREATMENT COST OF OVARIAN ENDOMETRIOSIS BASED ON REAL-WORLD HEALTH INSURANCE CLAIMS DATA

Csákvári T¹, Elmer D², Kajos L³, Pónusz R³, Pónusz-Kovács D³, Kovács B¹,
Sebestyén A¹, Bódis J¹, Boncz I¹

¹University of Pécs, Pécs, Hungary, ²University of Pécs, Pécs, PE, Hungary,

³University of Pécs, Pécs, BA, Hungary

OBJECTIVES

Direct and indirect costs of endometriosis can be substantial for both the individual and the health insurance provider(s) – especially since the treatment of endometriosis often requires costly inpatient care resources. The aim our study was to determine the annual health insurance treatment cost of ovarian endometriosis in Hungary.

METHODS

Data were derived from the financial database of the Hungarian National Health Insurance Fund Administration (NHIFA), for the year 2019. Data analysed included annual health insurance costs, patient numbers and cost distribution calculated for age groups. The following cost categories were included into the study: general practice care, home care, in- and outpatient care, medical imaging, laboratory diagnostics, pharmaceuticals and medical aids. Patients with ovarian endometriosis were identified with the following code of the International Classification of Diseases 10th revision: N80.1.

RESULTS

In 2019, the NHIFA spent 133.12 million Hungarian Forints (HUF) on the treatment of patients with ovarian endometriosis (458.01 thousand American Dollars [USD], or 409.16 thousand Euros [EUR]). The highest patient numbers were in outpatient care (1,608 women). Acute inpatient care (70.7% of total health insurance costs), use of pharmaceuticals (16.3%) and general practice care (5.1%) were the main cost drivers, while all other forms of medical care amounted to 8.0% in women. Annual health care treatment cost per patient was 82,786 HUF (285 USD/254 EUR) according to patient numbers of outpatient care. The highest annual health insurance costs were found in the '20-29' and '30-39' age groups.

CONCLUSIONS

Acute inpatient care utilisation was the major cost driver, which was 4.33 times higher than use of pharmaceuticals, 13.88 times as much as general practice care costs in 2019. In order to be able to reduce expenditures linked to ovarian - and other forms of – endometriosis, identifying risk factors and timely treatment are crucial.




Figure 1.
Distribution of the main cost drivers of ovarian endometriosis treatment in Hungary (2019)




Figure 2.
Comparison of total costs among different age groups (2019)




Figure 3.
Annual total health insurance treatment (and per patient) costs of ovarian endometrisosis amon different age groups (2019)

Type of care	Patient numbers (capita)	Expenditures (in USD)
Acute inpatient care	469	\$323,821
Pharmaceuticals	423	\$74,429
General practice care	1,519	\$23,270
Outpatient care	1,608	\$18,446
CT, MRI	73	\$12,926
Chronic inpatient care	4	\$2,657
Laboratory diagnostics	286	\$2,253
Patient transportation	1	\$129
Care in care centers	3	\$51
Medical aids	1	\$24
Home care	0	\$0
PET	0	\$0
Medicaments, disposable instruments and implantations falling under itemized accounts	0	\$0
TOTAL	--	\$458,006

Table 1.
Distribution of the annual health insurance treatment cost and patient numbers of ovarian endometriosis in Hungary according to type of care (2019)

ISPOR 2022
May 15-18, 2022
Washington, DC, USA Area and Virtual



Funding:
The research was financed by the National Laboratory for Human Reproduction (HRNL) established under the leadership of the University of Pécs.

Corresponding author:
Dr. Imre BONCZ, MD, MSc, PhD, Habil
University of Pécs, Faculty of Health Sciences, Hungary
Institute for Health Insurance
E-mail: imre.boncz@etk.pte.hu

